By proceeding, you agree to our Terms of Use and Privacy Policy.
Ben is Chief Technology Officer (CTO) at PhoreMost, a target identification and drug discovery company based in Cambridge, UK. He joined in 2019 to lead the evolution and development of a novel screening platform which uses intracellularly-expressed mini-proteins to discover unprecedented targets and to unlock new drug discovery strategies in targeted protein degradation. Prior to joining PhoreMost, Ben founded and led a CRISPR-based functional genomic screening department at Horizon Discovery, the leading UK gene editing biotech company based in Waterbeach, UK. Ben’s academic training was in chemical genetics, functional genomics and mechanisms of proteostasis, working in Cambridge and Manchester where Ben uncovered new modes of inhibition in the unfolded protein response.
Talks About #crispr #protac #biotech #proteostasis #drugdiscovery
Preferred Locations #Europe